MedTrace Logo

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

NCT05393804 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.

Conditions

Interventions

BIOLOGICAL

Ide-cel (bb2121)

Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.

Sponsors & Collaborators

Principal Investigators

  • Gunjan Shah, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393804 on ClinicalTrials.gov